Our corporate headquarters are located in Dublin, Ireland, and our U.S.
−Removed: operations are located in Palo Alto, California and Philadelphia, Pennsylvania.
−Removed: We lease approximately 45,000 square feet of office space in Dublin, Ireland.
−Removed: This lease expires in December 2036, with an option to terminate in December 2024 with no less than one year’s prior written notice and the payment of a termination fee, and a further option to terminate in December 2031 with no less than one year’s prior written notice.
−Removed: We own approximately 58,000 square foot of manufacturing and development facility in Athlone, Ireland, which is primarily used for the manufacture of Xyrem, Xywav and development-stage products.
−Removed: In Palo Alto, California, we occupy a total of approximately 198,000 square feet of office space, 99,000 square feet of which is under a lease that expires in October 2029 and has an option to terminate in October 2027 with no less than one year’s prior written notice and the payment of a termination fee.
−Removed: The remaining 99,000 square feet is under a lease that expires in July 2031 and an option to terminate in October 2029 with no less than one year’s prior written notice and the payment of a termination fee.
−Removed: We have an option to extend the terms of both leases twice for a period of five years each.
−Removed: We occupy approximately 60,000 square feet of office space in Philadelphia, Pennsylvania under a lease that expires in April 2029 with an option to terminate in December 2025 with no less than one year’s prior written notice and the payment of a termination fee.
−Removed: We occupy approximately 26,000 square feet of office space in Oxford, United Kingdom under a lease that expires in April 2028 with an option to terminate in April 2025 with six months written notice.
−Removed: We own a manufacturing facility in Villa Guardia (Como), Italy, which is primarily used for the manufacture of Defitelio.
−Removed: The manufacturing facility is approximately 45,000 square feet.
−Removed: We also lease approximately 34,000 square feet of office and laboratory space in Villa Guardia (Como), Italy under a lease that expires in December 2023.
−Removed: In addition, we have offices in Canada, France and elsewhere in Europe.
+Added: operations are located in Palo Alto, California, Carlsbad, California and Philadelphia, Pennsylvania.
+Added: In addition to our owned manufacturing and development facilities and our leased administrative, manufacturing and development facilities, we also have dedicated growing facilities operated by contract partners.
+Added: The following table contains information about our significant properties as of December 31, 2021:
+Added: Type Location Approximate Square Feet Lease / Contract
+Added: Expiration Date
+Added: Administrative office Dublin, Ireland 45,000 2036
+Added: Administrative office Palo Alto, United States 99,000 2029
+Added: Administrative office Carlsbad, United States 52,000 2023-2027
+Added: Administrative office Philadelphia, United States 60,000 2029
+Added: Administrative office Oxford, United Kingdom 26,000 2028
+Added: Administrative office Cambridge, United Kingdom 22,000 2030-2031
+Added: Administrative office London, United Kingdom 7,000 2028
+Added: Administrative office and laboratory Villa Guardia (Como), Italy 34,000 2023
+Added: Manufacturing and development Athlone, Ireland 58,000 Owned
+Added: Manufacturing and development Villa Guardia (Como), Italy 45,000 Owned
+Added: Manufacturing and development Southern United Kingdom 150,000 2022-2033
+Added: Growing facility Eastern United Kingdom 1,960,000 2023
+Added: Growing facility Northern United Kingdom 915,000 2022
+Added: Growing facility Southern United Kingdom 165,000 2028
+Added: Growing facility under construction Southern United Kingdom 370,000 2035
+Added: In addition, we have offices in Canada, Japan, Australia, France and elsewhere in Europe.
We believe that our existing properties are in good condition and suitable for the conduct of our business.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.